Literature DB >> 9629874

Delayed emesis following anticancer chemotherapy.

M G Kris1, F Roila, P H De Mulder, M Marty.   

Abstract

Delayed emesis is a distinct syndrome where vomiting begins or persists 24 or more hours after chemotherapy. It is more likely to occur when the stimulus for emesis is strong and/or acute vomiting is poorly controlled. The pathophysiology appears different than that which causes acute emesis. The literature reporting clinical trials to prevent delayed nausea and vomiting are presented. The best ways of preventing delayed emesis following anticancer chemotherapy are discussed.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9629874     DOI： 10.1007/s005200050158

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


  8 in total

1.  Meta-analysis of adjunctive non-NK1 receptor antagonist medications for the control of acute and delayed chemotherapy-induced nausea and vomiting.

Authors:  Thaiana Aragão Santana; Damila Cristina Trufelli; Leandro Luongo de Matos; Felipe Melo Cruz; Auro Del Giglio
Journal:  Support Care Cancer       Date:  2014-08-22       Impact factor: 3.603

Review 2.  Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.

Authors:  Mark G Kris; Paul J Hesketh; Jorn Herrstedt; Cynthia Rittenberg; Lawrence H Einhorn; Steven Grunberg; Jim Koeller; Ian Olver; Sussanne Borjeson; Enzo Ballatori
Journal:  Support Care Cancer       Date:  2004-11-23       Impact factor: 3.603

3.  Prevention of delayed emesis induced by moderately emetogenic chemotherapy in patients with acute emesis: a pilot study with ACTH-Depot plus tropisetron.

Authors:  D Santini; B Vincenzi; C Fossati; R M D'Angelillo; G Patti; V Bianco; G Avvisati; G Tonini
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

4.  Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study.

Authors:  Alessandra Fabi; Mario Barduagni; Salvatore Lauro; Luigi Portalone; Mariella Mauri; Filippo Marinis; Carla Narduzzi; Giuseppe Tonini; Marianna Giampaolo; Umberto Pacetti; Francesca Paoloni; Francesco Cognetti
Journal:  Support Care Cancer       Date:  2003-01-25       Impact factor: 3.603

Review 5.  Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice.

Authors:  E S Antonarakis; R D W Hain
Journal:  Arch Dis Child       Date:  2004-09       Impact factor: 3.791

6.  Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study.

Authors:  Alessandra Fabi; Mariangela Ciccarese; Giulio Metro; Antonella Savarese; Diana Giannarelli; Carmen M Nuzzo; Michelangelo Russillo; Isabella Sperduti; Ilaria Carbone; Emilio Bria; Francesco Cognetti
Journal:  Support Care Cancer       Date:  2008-05-14       Impact factor: 3.603

7.  Involvement of substance P in the development of cisplatin-induced acute and delayed pica in rats.

Authors:  Kouichi Yamamoto; Keiko Asano; Ayana Tasaka; Yuko Ogura; Seikou Kim; Yui Ito; Atsushi Yamatodani
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

8.  Cohort study of consistency between the compliance with guidelines for chemotherapy-induced nausea and vomiting and patient outcome.

Authors:  Masahiro Inoue; Manabu Shoji; Naomi Shindo; Kazunori Otsuka; Masatomo Miura; Hiroyuki Shibata
Journal:  BMC Pharmacol Toxicol       Date:  2015-03-28       Impact factor: 2.483
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.